Introduction: New insights, treatments, and management strategies for ADPKD

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 4, 2008, Pages 1195-1196

  Cowley Jr , Benjamin D ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CYCLIC AMP; HORMONE ANTAGONIST; RAPAMYCIN; VASOPRESSIN RECEPTOR;

APOPTOSIS; BODY FLUID; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; DRUG EFFECT; EDITORIAL; HUMAN; KIDNEY; KIDNEY POLYCYSTIC DISEASE; METABOLISM; NEPHROLOGY; PATHOLOGY; SECRETION; TREATMENT OUTCOME;

APOPTOSIS; BODY FLUIDS; CASPASES; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; CYCLIC AMP; HORMONE ANTAGONISTS; HUMANS; KIDNEY; NEPHROLOGY; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RECEPTORS, VASOPRESSIN; SIROLIMUS; TREATMENT OUTCOME;

EID: 49149092502     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00460108     Document Type: Editorial

References (6)

1. Cowley BD Jr: Recent advances in understanding the pathogenesis of polycystic kidney disease: Therapeutic implications. Drugs 64: 1285-1294, 2004
2. Chapman AB: Approaches to testing new treatments in autosomal dominant polycystic kidney disease: Insights from the CRISP and HALT studies. Clin J Am Soc Nephrol 3: 1197-1204, 2008
3. Calvet JP: Strategies to inhibit cyst formation in ADPKD. Clin J Am Soc Nephrol 3: 1205-1211, 2008
4. Torres VE: Role of vasopressin antagonists. Clin J Am Soc Nephrol 3: 1212-1218, 2008
5. Edelstein CL: Mammalian target of rapamycin and caspase inhibitors in polycystic kidney disease. Clin J Am Soc Nephrol 3: 1219-1226, 2008
6. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN: Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358: 140-151, 2008